🇺🇸 GERON CORPGERN

Company Update Form 8-K 28-10-2026 16:47:35 EDT

Subject: 8-K Items 8.01, 9.01

Overview: Corporation is discontinuing its Phase 3 IMpactMF trial of imetelstat in relapsed/refractory myelofibrosis following a Data Monitoring Committee recommendation.

Source: SEC EDGAR · Original filing

Open document in a new tab

Get filings like this in Telegram the moment they are published — for the companies you follow.

Start 30-day trial About Finterest